Supplementary Information

Attenuation of murine sclerodermatous models by the selective S1P1 receptor modulator cenerimod

Miyu Kano¹, Tadahiro Kobayashi¹, Mutsumi Date¹, Momoko Tennichi¹, Yasuhiro Hamaguchi¹, Daniel S Strasser², Kazuhiko Takehara¹, and Takashi Matsushita¹

¹Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-8641, Japan

²Idorsia Pharmaceuticals Ltd., Drug Discovery, Hegenheimermattweg 91, CH-4123 Allschwil, Switzerland

Running title: Selective S1P₁ receptor modulator attenuates Scleroderma mouse models

¹Address correspondence to: Takashi Matsushita, MD, PhD, Department of Dermatology, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa 920-8641, Japan

Phone: 81-76-265-2343 Fax: 81-76-234-4270
E-mail: t-matsushita@med.kanazawa-u.ac.jp
Supplementary Figure 1. (A, B) The Scl-cGVHD skin disease (Bs1) and the cenerimod (Bs3) gene expression effect was compared to a gene expression data set derived from murine Scl-cGVHD Treg cells (GSE16210 = Bs2). The analysis using Correlation Engine are showed. All data are representative of two independent experiments.